IASO Bio, Innovent CAR T-cell therapy receives orphan drug designation

By The Science Advisory Board staff writers

February 15, 2022 -- IASO Biotherapeutics and Innovent Biologics jointly announced that the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to their fully human, anti-B-cell maturation antigen (BCMA), CAR T-cell therapy CT103A/IBI326 for the treatment of relapsed and/or refractory multiple myeloma (R/R MM).

CT103A has been developed to address the adverse events and reinfusion challenges of previous high-dose BCMA-targeting CAR T cells. CT103A is a lentiviral vector containing a CAR structure with a fully human, single-chain variable fragment (scFv), CD8a hinger and transmembrane, 4-1BB co-stimulatory, and CD3ζ activation domains. Based on strict selection and screening, utilizing a proprietary in-house optimization platform, the construct of the BCMA CAR T is potent and persistent, the companies stated.

The designation will accelerate drug development and registration action of CT103A in the U.S. CT103A will be eligible for certain development incentives, including FDA support for clinical studies, a waiver or reduction of registration application fee, and a seven-year U.S. market exclusivity granted upon product approval. CT103A was also granted breakthrough therapy designation by China's National Medical Products Administration for the treatment of R/R MM.

Amagma Therapeutics announces strategic partnership with Innovent Biologics
Amagma Therapeutics has entered into a license option agreement with Innovent Biologics for up to three enzyme-specific inhibitors derived from Amagma's...
Bolt Bio, Innovent collaborate on oncology agents
Bolt Biotherapeutics and Innovent Biologics are collaborating to develop three anticancer drug candidates based on Bolt's therapeutic immune-stimulating...
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...
Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter